Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Melatonin has been studied in recent years for its potential role in supporting or treating glaucoma, a condition characterized by increased intraocular pressure (IOP) and progressive optic nerve damage. Scientific evidence, primarily from animal studies and a few small human trials, indicates that melatonin and its analogs may help lower IOP—a key therapeutic goal in glaucoma management. The proposed mechanism involves melatonin's action on specific ocular receptors (MT1, MT2, and MT3) that regulate aqueous humor dynamics, leading to decreased fluid production or increased outflow within the eye. Additionally, melatonin’s antioxidant properties may offer neuroprotection to retinal ganglion cells, potentially slowing optic nerve damage. However, the strength of the evidence is still moderate to low. Most studies have been preclinical, using animal models or in vitro systems. A handful of small clinical studies have shown promising results, such as modest reductions in IOP in glaucoma patients after melatonin supplementation, but these need replication in larger, controlled trials. Melatonin is not currently a standard or approved treatment for glaucoma, and its long-term efficacy and safety for this indication remain uncertain. In summary, while there is a scientific basis and preliminary evidence supporting melatonin’s potential benefit for glaucoma, its clinical use is not yet established, and more robust studies are needed before it can be recommended as a routine therapy.

More about melatonin
More about Glaucoma

Other ingredients used for Glaucoma

Other health conditions supported by melatonin

Products containing melatonin

Nature's Sunshine Melatonin Extra